BioMend® - Clinical Research Data Summary

BIOMend® is a clinically studied ingredient used in the following Silver Fern™ Brand product:

Introduction

BIOMend® is a novel butyrate delivery system composed of a lysine–butyrate complex designed to enhance the stability, tolerability, and systemic availability of butyric acid. Butyrate is a critical short-chain fatty acid produced by the gut microbiota and is essential for intestinal barrier integrity, immune regulation, and metabolic signaling. Reduced butyrate availability has been consistently observed in conditions such as inflammatory bowel disease, metabolic syndrome, obesity, and other states of chronic low-grade inflammation.

While conventional butyrate salts and triglyceride forms have demonstrated biological activity, their practical use has been limited by unpleasant sensory properties, rapid proximal absorption, and inconsistent systemic exposure. BIOMend® was developed to address these challenges by pairing butyrate with lysine, an essential amino acid, to improve palatability and absorption characteristics. Human pharmacokinetic data demonstrate that lysine butyrate delivers butyrate into circulation rapidly and at higher peak concentrations compared with some alternative formulations, supporting its relevance for both local gut effects and systemic signaling pathways. Through these properties, BIOMend® represents a next-generation postbiotic ingredient aimed at restoring butyrate signaling in a form suitable for real-world, daily use.

These are the studies for BIOMend®. Below, we provided a summary of each key data for each study, along with a link to the complete clinical research.

  1. Summary of Study 1 – Full Script: https://www.nature.com/articles/ncomms10062
  2. Summary of Study 2 – Full Script: https://pubs.rsc.org/en/content/articlelanding/2021/fo/d1fo02116h
  3. Summary of Study 3 – Full Script: https://pubmed.ncbi.nlm.nih.gov/37542852/
  4. Summary of Study 4 – Full Script: https://pubmed.ncbi.nlm.nih.gov/19625695/
  5. Summary of Study 5 – Full Script: https://www.researchgate.net/publication/375885731
  6. Summary of Study 6 – Full Script: https://pubmed.ncbi.nlm.nih.gov/32476236/
  7. Summary of Study 7 – Full Script: https://pubmed.ncbi.nlm.nih.gov/36469320/
  8. Summary of Study 8 – Full Script: https://pubmed.ncbi.nlm.nih.gov/39003477/
  9. Summary of Study 9 – Full Script: https://www.nature.com/articles/s41598-018-37246-7
  10. Summary of Study 10 – Full Script: https://journalofexerciseandnutrition.com/index.php/JEN/article/view/189
  11. Summary of Study 11 – Full Script: https://pubmed.ncbi.nlm.nih.gov/41422374/
  12. Summary of Study 12 – Full Script: https://pubmed.ncbi.nlm.nih.gov/24343275/
  13. Summary of Study 13 – Full Script: https://pubmed.ncbi.nlm.nih.gov/36014789/
  14. Summary of Study 14 – Full Script: https://pmc.ncbi.nlm.nih.gov/articles/PMC11930386/

Ingredient Manufacturer Link: https://nutrashure.com/ingredients/biomend/



Study 1 Summary

Complete Study Information: https://www.nature.com/articles/ncomms10062

Production of butyrate from lysine and the Amadori product fructoselysine by a human gut commensal. Nature Communications. 2015;6:10062.

This study investigated a previously unrecognized metabolic pathway by which certain human gut commensal bacteria can convert the amino acid lysine and its glycation product fructoselysine into butyrate, a key short-chain fatty acid essential for gut and immune health. Using a combination of genomic, proteomic, and metabolic analyses, the researchers identified specific bacterial enzymes and pathways responsible for this conversion. The findings expand the understanding of butyrate production beyond carbohydrate fermentation alone, demonstrating that dietary amino acids can also serve as biologically relevant precursors for butyrate generation in the human colon, with important implications for gut barrier integrity, immune regulation, and metabolic health.

Detailed Study Summary

  • Study Type: Mechanistic, in vitro and ex vivo microbial metabolism study
  • Subjects: Human gut commensal bacteria (not a human intervention trial)
  • Dosing: Not applicable (cellular/microbial metabolism study)
  • Duration: Metabolic assessments conducted during bacterial growth cycles

Key Findings & Improvements

  • Identified a previously unknown butyrate-producing pathway derived from lysine metabolism.
  • Demonstrated that lysine and fructoselysine were efficiently converted into butyrate by specific gut microbes.
  • Showed that amino acid–derived butyrate production is quantitatively meaningful, not merely a trace or incidental pathway.
  • Expanded known butyrate sources beyond dietary fiber fermentation.

Percent improvements:
This study did not report percentage improvements, as it was not a clinical intervention. Outcomes were biochemical and mechanistic rather than symptom- or biomarker-based.

Conclusion

The findings establish lysine as a biologically relevant precursor to butyrate production in the human gut, revealing a complementary pathway to fiber fermentation. This supports the concept that butyrate availability in the colon can be enhanced through targeted amino acid delivery, particularly in individuals with compromised fiber tolerance or dysbiosis.

Practical, Real-World Relevance

This study has several highly actionable implications:

  • Supports lysine-butyrate formulations (like BIOMend®):
    Demonstrates that lysine is not just a carrier but a functional contributor to butyrate biology.
  • Relevant for low-fiber or low-FODMAP individuals:
    Provides a pathway to butyrate production without reliance on fermentable fibers, which many people with SIBO, IBS, or gut sensitivity cannot tolerate.
  • Gut barrier & immune tolerance support:
    By increasing butyrate availability, lysine-derived pathways may help support:
    • Tight junction integrity
    • Regulatory T-cell activity
    • Reduced inappropriate immune activation
  • Metabolic flexibility of the microbiome:
    Highlights how the gut microbiome can adaptively use dietary amino acids to maintain SCFA production under suboptimal conditions.

Reference Link: https://www.nature.com/articles/ncomms10062



Study 2 Summary

Complete Study Information: https://pubs.rsc.org/en/content/articlelanding/2021/fo/d1fo02116h

A new paradigm for a new simple chemical: butyrate & immune regulation.
Food & Function. 2021;12(24):12181–12193.
doi:10.1039/d1fo02116h

This review paper synthesizes a broad body of mechanistic and translational research demonstrating how butyrate, a key short-chain fatty acid produced by the gut microbiota, regulates immune function, inflammation, metabolic health, and neurological processes. The authors detail how butyrate enters cells via SLC5A8 transporters, acts as a histone deacetylase (HDAC) inhibitor, and suppresses NF-κB–mediated inflammatory signaling, leading to reduced expression of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. Additionally, butyrate functions as a signaling molecule through G-protein–coupled receptors (GPR41, GPR43, GPR109), promoting anti-inflammatory pathways, immune tolerance, and tissue homeostasis. The paper highlights butyrate's relevance across intestinal health, obesity, immune regulation, and brain-related disorders, positioning it as a central mediator of host–microbiome communication.

Key Conclusions

  • Butyrate:
    • Suppresses pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) via HDAC inhibition and NF-κB down-regulation
    • Activates anti-inflammatory signaling through GPR41, GPR43, and GPR109
    • Reduces chemokine expression and inflammatory immune cell recruitment
    • Supports immune tolerance, gut barrier integrity, and metabolic regulation
  • The authors conclude that butyrate is a central immune-regulatory metabolite with therapeutic relevance across inflammatory, metabolic, and neurological disorders.

Practical, Real-World Relevance

This paper has strong real-world applicability despite not being a clinical trial:

  • Supports butyrate supplementation strategies:
    Confirms multiple mechanisms by which increasing butyrate availability can calm immune overactivation and chronic inflammation.
  • Relevant for gut barrier and leaky gut protocols:
    Reinforces butyrate's role in maintaining epithelial integrity and reducing inflammatory signaling at the intestinal level.
  • Applicable to metabolic and obesity-related inflammation:
    Links butyrate signaling to improved immune–metabolic balance, relevant for insulin resistance and adipose inflammation.
  • Gut–brain axis relevance:
    Highlights pathways through which butyrate may influence neurological and cognitive health by modulating inflammation and epigenetic signaling.
  • Justifies non-fiber butyrate delivery:
    Especially relevant for individuals who cannot tolerate fermentable fibers (e.g., SIBO, IBS), supporting direct or stabilized butyrate forms like lysine butyrate.

Reference Link: https://pubs.rsc.org/en/content/articlelanding/2021/fo/d1fo02116h



Study 3 Summary

Complete Study Information: https://pubmed.ncbi.nlm.nih.gov/37542852/

The impact of microbiota-derived short-chain fatty acids on macrophage activities in disease.
Biomedicine & Pharmacotherapy. 2023;165:115276.
doi:10.1016/j.biopha.2023.115276

This comprehensive review examines how microbiota-derived short-chain fatty acids (SCFAs)—particularly butyrate, propionate, and acetate—regulate immune and inflammatory processes through their effects on macrophage activity and immune cell differentiation. The authors highlight how SCFAs influence key immune pathways by modulating T-cell polarization, dendritic cell signaling, macrophage phenotype switching, and epigenetic regulation via histone deacetylase (HDAC) inhibition. The review integrates findings from cellular, animal, and translational research showing that SCFAs can suppress excessive inflammatory responses, promote immune tolerance, enhance antimicrobial defense mechanisms, and influence disease progression in conditions ranging from allergic airway inflammation to infectious diseases and cancer. Collectively, the paper positions SCFAs as central mediators of host–microbiome immune communication with significant therapeutic potential.

Key Findings

  • Butyrate:
    • Reduces IFN-γ–producing immune cells
    • Promotes differentiation of regulatory T (Treg) cells
  • Propionate:
    • Inhibits Th2 immune response initiation by dendritic cells
  • SCFAs broadly:
    • Modulate macrophage polarization and immune tone
    • Enhance antimicrobial activity via HDAC inhibition and HIF-1 activation
    • Improve macrophage-mediated pathogen clearance
  • Dysregulated SCFA production due to microbiome imbalance is linked to altered immune responses and disease progression in inflammatory and oncologic contexts

Conclusion

The authors conclude that SCFAs act as powerful immunomodulatory metabolites capable of shaping macrophage behavior, immune tolerance, and antimicrobial defense. By influencing epigenetic regulation and immune cell signaling, SCFAs help maintain immune homeostasis and represent promising targets for future microbiome-based and postbiotic therapeutic strategies.

Practical, Real-World Relevance

This paper offers several highly applicable takeaways:

  • Supports postbiotic strategies for immune balance:
    Reinforces the value of increasing SCFA availability to support regulated immune responses rather than immune overstimulation.
  • Relevant for inflammatory and allergic conditions:
    Highlights mechanisms by which SCFAs help prevent excessive Th2-driven immune activity and inflammatory signaling.
  • Gut–immune–microbiome connection:
    Demonstrates how gut-derived metabolites directly influence immune cell behavior throughout the body.
  • Antimicrobial defense support:
    Shows how SCFAs enhance macrophage-mediated pathogen clearance and antibacterial effector production.
  • Justifies SCFA support beyond fiber fermentation:
    Particularly relevant for individuals with dysbiosis, low SCFA production, or fiber intolerance—supporting direct or stabilized postbiotic approaches (e.g., butyrate delivery).

Reference Link: https://pubmed.ncbi.nlm.nih.gov/37542852/



Study 4 Summary

Complete Study Information: https://pubmed.ncbi.nlm.nih.gov/19625695/

Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009 Sep;139(9):1619-25. doi: 10.3945/jn.109.104638. Epub 2009 Jul 22. PMID: 19625695; PMCID: PMC2728689.

This study investigated the molecular mechanisms by which butyrate strengthens intestinal barrier function, focusing on its effects on tight junction assembly in intestinal epithelial cells. Using human Caco-2 cell monolayers as a model of the intestinal barrier, the researchers demonstrated that butyrate significantly enhanced tight junction integrity by activating AMP-activated protein kinase (AMPK), a key cellular energy and stress-sensing enzyme. Activation of AMPK promoted the assembly and organization of tight junction proteins, leading to reduced intestinal permeability. These findings provided early mechanistic evidence that butyrate directly supports epithelial barrier integrity at the cellular level, independent of immune modulation.

Detailed Study Summary

Study Type

  • In vitro mechanistic study (human intestinal epithelial cell model)

Dosing

  • Butyrate concentrations ranged from 2–5 mM, reflecting physiologically relevant levels found in the human colon

Time of Use

  • Short-term exposure (hours to days), sufficient to observe changes in tight junction assembly and barrier function

Percentage Improvements

  • Percentage improvements were not reported. Outcomes were measured using:
    • Transepithelial electrical resistance (TEER)
    • Tight junction protein localization
    Results were expressed as significant increases in barrier integrity, not percentage-based clinical improvements.

Key Findings

  • Butyrate significantly:
    • Increased transepithelial electrical resistance (TEER), indicating improved barrier function
    • Enhanced assembly and organization of tight junction proteins
    • Activated AMPK signaling pathways
  • Inhibition of AMPK blocked the barrier-enhancing effects of butyrate, confirming AMPK as a key mediator

Conclusion

The study concluded that butyrate directly enhances intestinal epithelial barrier integrity by activating AMPK and facilitating tight junction assembly. This mechanism provides a clear biological explanation for butyrate's protective role in maintaining gut barrier function and preventing increased intestinal permeability.

Practical, Real-World Relevance

Despite being a cell-based study, this paper has strong real-world implications:

  • Supports gut barrier and "leaky gut" support strategies:
    Demonstrates a direct cellular mechanism by which butyrate helps maintain tight junction integrity.
  • Relevant for inflammatory and immune balance protocols:
    Improved barrier function reduces the likelihood of immune activation from luminal antigens.
  • Justifies direct butyrate or postbiotic delivery:
    Especially relevant for individuals with low endogenous butyrate production or impaired fermentation.
  • Energy and stress signaling relevance:
    AMPK activation links butyrate to broader metabolic and cellular resilience pathways.
  • Foundational substantiation:
    This study is frequently cited to support claims around intestinal barrier support, making it highly valuable for scientific credibility.

Reference Link: https://pubmed.ncbi.nlm.nih.gov/19625695/



Study 5 Summary

Complete Study Information: https://www.researchgate.net/publication/375885731

Modulation of GABA by sodium butyrate ameliorates hypothalamic inflammation in an experimental model of PCOS.
BMC Neuroscience. 2023;24(1):62.
doi:10.1186/s12868-023-00834-z

This study evaluated whether oral sodium butyrate could modulate neuroinflammation and GABAergic signaling in a letrozole-induced rat model of polycystic ovary syndrome (PCOS). Animals receiving sodium butyrate supplementation showed significant reductions in hypothalamic inflammatory markers, decreased microglial activation, and improvements in markers of GABAergic neurotransmission. These effects were associated with reduced expression of pro-inflammatory cytokines and were linked to butyrate's histone deacetylase (HDAC) inhibitory activity. The findings suggest that butyrate may support neuroimmune balance through modulation of inflammation and neurotransmitter-related signaling pathways in the central nervous system.

Detailed Study Summary

Study Type:
Preclinical animal study (rat model of PCOS)

Dosing:
Sodium butyrate administered orally at 300 mg/kg body weight per day

Time of Use:
Approximately 6 weeks following PCOS induction

Percentage Improvements:
Statistically significant reductions in hypothalamic pro-inflammatory cytokines (including TNF-α and IL-1β) and microglial activation markers. Outcomes were reported as relative changes compared to untreated PCOS animals rather than consumer-relevant percentage improvements.

Key Findings:

  • Sodium butyrate reduced hypothalamic inflammation
  • Improved markers of GABAergic signaling
  • Decreased pro-inflammatory cytokine expression
  • Supported neuroimmune signaling pathways linked to metabolic and hormonal regulation
  • Effects were associated with HDAC inhibition and anti-inflammatory mechanisms

Conclusion:
The authors concluded that sodium butyrate attenuates hypothalamic inflammation and supports GABA-mediated neuroimmune signaling in a PCOS animal model, highlighting a potential role for butyrate in supporting neuroendocrine and immune balance.

Practical, Real-World Relevance

  • Supports the role of butyrate in gut–brain–neuroimmune communication
  • Demonstrates how microbiota-derived metabolites may influence central inflammatory signaling
  • Provides mechanistic support for postbiotic strategies focused on neuroimmune balance
  • Relevant to stress, sleep, and mood pathways via GABA-related signaling
  • Mechanistic, preclinical evidence appropriate for structure/function substantiation, not disease claims

Reference Link: https://www.researchgate.net/publication/375885731



Study 6 Summary

Complete Study Information: https://pubmed.ncbi.nlm.nih.gov/32476236/

Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease.
Neurogastroenterology & Motility. 2020;32(10):e13914.
doi:10.1111/nmo.13914

This clinical study investigated the effects of oral microencapsulated sodium butyrate on gut microbiota composition and clinical outcomes in patients with inflammatory bowel disease (IBD). Because butyrate is rapidly absorbed in the upper gastrointestinal tract, the researchers used a microencapsulated formulation designed to improve delivery to the colon. Over the intervention period, supplementation with sodium butyrate led to meaningful shifts in gut microbiota composition, particularly increasing the abundance of butyrate-producing bacterial taxa, alongside improvements in patient-reported quality-of-life measures. The findings suggest that oral butyrate supplementation may positively influence the gut microbial ecosystem and support intestinal health in individuals with chronic inflammatory conditions.

Detailed Study Summary

Study Type

  • Human clinical intervention study (patients with inflammatory bowel disease)

Dosing

  • 1,800 mg/day of microencapsulated sodium butyrate, administered orally

Time of Use

  • 60 days of continuous supplementation

Percentage Improvements

  • Exact percentage improvements were not the primary reporting metric.
  • Results were reported as:
    • Significant increases in the relative abundance of butyrate-producing bacterial genera, including Butyricoccus and members of the Lachnospiraceae family
    • Improvements in patient-reported quality-of-life scores
  • Microbiota changes were expressed as relative abundance shifts, not consumer-style percentage symptom reductions

Key Findings

  • Sodium butyrate supplementation:
    • Increased populations of beneficial, SCFA-producing gut bacteria
    • Improved overall gut microbial balance
    • Was well tolerated with no significant adverse effects
  • The results suggest a positive feedback loop, where exogenous butyrate supports endogenous butyrate-producing microbes

Conclusion

The authors concluded that microencapsulated sodium butyrate favorably modulates gut microbiota composition and improves quality-of-life parameters in patients with IBD, supporting its role as a gut-targeted postbiotic capable of enhancing intestinal microbial and functional balance.

Practical, Real-World Relevance

This study has strong translational value:

  • Human clinical validation:
    Confirms that oral butyrate supplementation can meaningfully influence the gut microbiome in real patients.
  • Supports gut barrier & microbiome resilience strategies:
    Increasing butyrate-producing bacteria helps reinforce intestinal ecosystem stability.
  • Relevant for sensitive or inflamed guts:
    Demonstrates tolerability and benefit even in individuals with chronic GI conditions.
  • Delivery matters:
    Highlights the importance of protected or stabilized butyrate forms to reach the colon effectively.
  • Justifies postbiotic use beyond fiber:
    Particularly relevant for individuals who cannot tolerate high-fiber or fermentable prebiotics.

Reference Link: https://pubmed.ncbi.nlm.nih.gov/32476236/



Study 7 Summary

Complete Study Information: https://pubmed.ncbi.nlm.nih.gov/36469320/

Therapeutic Effects of Butyrate on Pediatric Obesity: A Randomized Clinical Trial.
JAMA Network Open. 2022;5(12):e2244912.
doi:10.1001/jamanetworkopen.2022.44912

Pediatric obesity is a growing global health concern, closely linked to early insulin resistance, chronic low-grade inflammation, and long-term cardiometabolic risk. Emerging evidence suggests that gut-derived metabolites—particularly short-chain fatty acids such as butyrate—play a critical role in metabolic regulation, appetite signaling, immune balance, and insulin sensitivity. The 2022 randomized clinical trial published in JAMA Network Open investigated whether oral butyrate supplementation could provide therapeutic benefit in children and adolescents with obesity when added to standard lifestyle-based care. Using a quadruple-blind, placebo-controlled design over a 6-month period, the study evaluated the effects of weight-adjusted sodium butyrate on BMI reduction, metabolic markers, inflammatory mediators, and appetite-related hormones.

The findings demonstrate that butyrate supplementation significantly increased the likelihood of clinically meaningful BMI reduction and led to improvements in insulin resistance, central adiposity, systemic inflammation, and appetite regulation compared with placebo. These results provide some of the strongest clinical evidence to date that targeted butyrate delivery may represent a safe, adjunctive strategy for improving metabolic health in pediatric obesity.

Dosing & Duration

  • Intervention: Oral sodium butyrate supplementation
  • Dose: 20 mg per kg body weight per day (up to ~800 mg/day maximum)
  • Duration: 6 months alongside standard care for pediatric obesity

Primary Outcome: BMI Change

Goal: ≥ 0.25 decrease in BMI standard deviation (SD) score over 6 months.

  • Butyrate group: 96% achieved this reduction
  • Placebo group: 56% achieved this reduction
  • Absolute benefit increase: +40% (statistically significant)

This means children receiving butyrate were significantly more likely to reduce BMI score beyond the expected change from standard lifestyle support alone.

Secondary Outcomes & Percent Improvements

At 6 months, among participants who completed the protocol:

Measure Butyrate vs Placebo Direction of Effect
Waist circumference −5.07 cm Lower abdominal fat
Fasting insulin −5.41 μU/mL Improved insulin levels
HOMA-IR (insulin resistance) −1.14 Better glucose regulation
Ghrelin (appetite hormone) −47.89 μg/mL Reduced hunger signaling
IL-6 (inflammation) −4.81 pg/mL Lower systemic inflammation
microRNA-221 −2.17 Potential metabolic regulatory change

All changes above were statistically significant (P<0.05) and favored the butyrate group.

Mechanistic Insights

The study also explored gut microbiome signatures and found that children with higher baseline levels of butyrate-producing bacteria tended to respond better to supplementation — suggesting that existing microbiome composition may influence effectiveness.

Safety & Tolerability

  • Adverse effects: Mild and transient nausea or headache in 2 children in the butyrate group during the first month
  • No serious safety issues reported

Conclusions from the Study

The authors conclude that oral butyrate supplementation (20 mg/kg daily) added to standard care may:

  • Increase the likelihood of reducing BMI in children with obesity
  • Improve metabolic health markers (insulin sensitivity, inflammation)
  • Influence appetite-related hormones and metabolic regulators
  • Potentially work better when the gut microbiome is already favorable for butyrate production

Real-World Relevance

Metabolic Health

  • Improved insulin sensitivity may reduce risk of pre-diabetes/Type 2 diabetes in children at high metabolic risk.
  • Lower HOMA-IR reflects better glucose regulation — a clinically meaningful improvement.

Reduced Inflammation

  • Lower IL-6 suggests reduced chronic inflammation, which is central to obesity-related complications.

Appetite Regulation

  • Reduced ghrelin levels may help with sustained appetite control, potentially aiding ongoing weight management.

Body Composition

  • A ~5 cm reduction in waist circumference indicates less central adiposity, an important target in obesity therapy.

Limitations & Considerations

  • Lack of direct body composition or energy expenditure measurement limits understanding of how fat vs lean mass changed.
  • Butyrate's taste and smell can make compliance challenging; future formulations may be needed.
  • Longer-term benefits and outcomes beyond 6 months were not assessed.

Reference Link: https://pubmed.ncbi.nlm.nih.gov/36469320/



Study 8 Summary

Complete Study Information: https://pubmed.ncbi.nlm.nih.gov/39003477/

Effects of short-chain fatty acid-butyrate supplementation on expression of circadian-clock genes, sleep quality, and inflammation in patients with active ulcerative colitis.
Lipids in Health and Disease. 2024;23(1):216.
doi:10.1186/s12944-024-02203-z

Ulcerative colitis is a chronic inflammatory bowel disease frequently accompanied by disrupted circadian rhythms, poor sleep quality, and persistent intestinal inflammation. The 2024 randomized, double-blind, placebo-controlled trial published in Lipids in Health and Disease evaluated the effects of oral sodium butyrate supplementation over 12 weeks in patients with active ulcerative colitis. Results demonstrated that butyrate supplementation significantly reduced markers of intestinal and systemic inflammation, upregulated key circadian-regulatory genes, and led to meaningful improvements in sleep quality and patient-reported quality of life compared with placebo. Collectively, these findings suggest that butyrate may offer a novel, multi-system adjunctive strategy in ulcerative colitis management, extending benefits beyond inflammation control to circadian and sleep regulation.

Study Overview

Design: Double-blind, randomized, placebo-controlled trial
Population: 36 adults with active ulcerative colitis
Purpose: To assess whether oral sodium butyrate alters inflammatory markers, circadian-clock gene expression, sleep quality, and quality of life in UC patients.

Dosing & Duration

  • Supplement: Sodium butyrate
  • Dose: 600 mg/kg body weight per day
  • Duration: 12 weeks
  • Comparator: Placebo
  • Assessments:
    • Inflammation: faecal calprotectin, high-sensitivity C-reactive protein (hs-CRP)
    • Circadian gene expression: CRY1, CRY2, PER1, PER2, BMAL1, CLOCK (fold-change via qPCR)
    • Sleep quality: Pittsburgh Sleep Quality Index (PSQI)
    • Quality of Life (QoL): IBD Questionnaire-9 (IBDQ-9)

Key Results & Percent Changes

Inflammation Markers

  • Faecal Calprotectin (µg/g):
    • Butyrate: −133.8 ± 155.6
    • Placebo: +51.6 ± 95.6
    → Large net reduction in intestinal inflammation with butyrate (P < 0.001).
  • hs-CRP (mg/L):
    • Butyrate: −0.36 (median change)
    • Placebo: +0.48 (median change)
    → Reduced systemic inflammation compared with placebo (P < 0.001).

Circadian Clock Gene Expression (Fold Change vs Baseline)

Greater upregulation with butyrate vs placebo:

Gene Butyrate Placebo
CRY1 2.22 ± 1.59 0.63 ± 0.49
CRY2 2.15 ± 1.26 0.93 ± 0.80
PER1 1.86 ± 1.77 0.65 ± 0.48
BMAL1 1.85 ± 0.97 0.86 ± 0.63

→ Gene expression roughly 2–3× higher in key circadian regulators with butyrate.

Sleep Quality (PSQI)

  • Butyrate: −2.94 ± 3.50 (improvement)
  • Placebo: +1.16 ± 3.61 (worsened)

→ Clinically meaningful enhancement in sleep quality (P < 0.001).

Quality of Life (IBDQ-9)

  • Butyrate: +17.00 ± 11.36
  • Placebo: −3.50 ± 6.87

→ Substantial QoL improvement with butyrate supplementation (P < 0.001).

Conclusion of the Trial

This clinical trial shows that 12 weeks of oral sodium butyrate supplementation in patients with active UC was associated with:

  • Reduced intestinal and systemic inflammation
  • Upregulation of circadian-clock gene expression
  • Meaningful improvements in sleep quality
  • Large improvements in disease-related quality of life

Real-World Relevance & Practical Benefits

1. Inflammation Control

Butyrate's significant reduction in calprotectin and hs-CRP, both clinically used inflammatory biomarkers, implies better disease control and potentially fewer flare symptoms.

2. Better Sleep

Sleep disturbances are common in UC and can worsen symptoms; the substantial PSQI improvement suggests butyrate may help restore restful sleep and thereby improve recovery and quality of life.

3. Circadian Rhythm Regulation

Upregulated clock genes (like CRY1, CRY2, PER1, BMAL1) suggest butyrate could help normalize circadian biology, which is tied to immune regulation, hormone balance, and gut motility—areas often disrupted in chronic inflammatory conditions.

4. Enhanced Quality of Life

The large positive shift in IBDQ-9 scores (vs decline in placebo) underscores a perceived improvement in daily living and functional outcomes for patients.

Limitations & Considerations

  • Sample size was modest (n=36), so larger trials are needed for broader generalization.
  • Gene expression changes do not directly equate to protein function—but they indicate a shift in regulatory biology.
  • This study focused on active UC; results may differ in remission or other IBD subtypes.

Reference Link: https://pubmed.ncbi.nlm.nih.gov/39003477/



Study 9 Summary

Complete Study Information: https://www.nature.com/articles/s41598-018-37246-7

Effects of oral butyrate supplementation on inflammatory potential of circulating peripheral blood mononuclear cells in healthy and obese males.
Scientific Reports. 2019;9:775.
https://doi.org/10.1038/s41598-018-37246-7

Chronic low-grade inflammation and maladaptive innate immune activation are central features of metabolic syndrome and obesity. In this human intervention study, obese men with metabolic syndrome and lean controls received oral sodium butyrate supplementation for four weeks, after which peripheral blood mononuclear cells were analyzed for cytokine production and trained immunity responses. The results showed that butyrate supplementation significantly attenuated oxidized LDL- and β-glucan–induced trained immunity in monocytes from metabolically compromised individuals, particularly reducing pro-inflammatory cytokine responses, while having minimal effects in lean participants. These findings suggest that oral butyrate can selectively downregulate maladaptive immune memory associated with metabolic dysfunction, supporting its potential role as a systemic anti-inflammatory strategy in metabolic syndrome.

Study Overview

Focus: Systemic anti-inflammatory effects of oral sodium butyrate in humans
Population:

  • 9 lean healthy males
  • 10 obese males with metabolic syndrome (MetSyn)

Design: Pre–post intervention trial (no placebo control)
Duration: 4 weeks

Dosing & Time of Use

  • Supplement: Sodium butyrate
  • Dose: 4 grams per day (oral)
  • Duration: 4 weeks

Results: Direction & Magnitude of Change

Inflammatory Trained Immunity (MetSyn Group Only)

Compared with baseline, sodium butyrate supplementation:

  • Reduced oxLDL-induced trained immunity:
    • ↓ IL-6 response after LPS stimulation
    • ↓ TNF-α response after Pam3CSK4 stimulation
  • Reduced β-glucan–induced trained immunity:
    • ↓ IL-10 response after Pam3CSK4 stimulation

These reductions were statistically significant and selective to the metabolic syndrome group.

Lean vs Metabolic Syndrome

  • Lean subjects: Minimal immune changes
  • MetSyn subjects: Clear reduction in pro-inflammatory trained immunity

Conclusion of the Study

Four weeks of high-dose oral sodium butyrate supplementation significantly reduced maladaptive trained immunity responses in circulating monocytes of obese individuals with metabolic syndrome, particularly those driven by oxidized LDL. While direct cytokine stimulation was only modestly affected, the targeted reduction in trained innate immune responses suggests that butyrate may lower systemic inflammatory tone in metabolically compromised individuals without impairing baseline immune function.

Real-World Relevance & Practical Benefits

1. Targets Root Inflammation in Metabolic Syndrome

This study shows that butyrate can reprogram immune memory, not just lower inflammatory markers temporarily. That's critical because metabolic syndrome is driven by persistent immune activation, not acute inflammation.

2. Relevance to Cardiovascular Risk

oxLDL-trained immunity plays a role in foam cell formation, plaque instability, and endothelial dysfunction. Reducing this response suggests potential benefit for cardiometabolic risk reduction, even without changes in weight.

3. Selective, Not Immunosuppressive

Butyrate reduced harmful immune training only in metabolically dysregulated individuals, while leaving lean subjects largely unchanged — a strong safety signal.

4. Supports Postbiotic & Butyrate-Based Strategies

This study provides human evidence that oral butyrate can act systemically, supporting postbiotic formulations, butyrate-enhancing prebiotics, and encapsulated or sustained-release butyrate strategies.

5. Rapid Effect

Meaningful immune changes occurred in just 4 weeks, suggesting butyrate can influence immune tone relatively quickly.

Key Limitations

  • Small sample size
  • Male-only population
  • No placebo group
  • No clinical endpoints measured

This is a mechanistic proof-of-concept study, not a therapeutic outcomes trial — but a very strong one for immune biology.

Reference Link: https://www.nature.com/articles/s41598-018-37246-7



Study 10 Summary

Complete Study Information: https://journalofexerciseandnutrition.com/index.php/JEN/article/view/189

Pharmacokinetics of different butyrate formulations: a randomized crossover trial. Journal of Exercise and Nutrition. 2023;6(2):189.

The clinical effectiveness of butyrate supplementation depends not only on dose but also on formulation, bioavailability, and systemic exposure. A randomized, crossover pharmacokinetic study published in the Journal of Exercise and Nutrition evaluated serum butyrate responses following a single oral dose of lysine butyrate, sodium butyrate, or tributyrin, each delivering an equivalent amount of butyric acid. The study demonstrated that lysine butyrate achieved more rapid absorption and higher peak circulating butyrate concentrations compared with tributyrin, and comparable or superior exposure relative to sodium butyrate. These findings highlight the importance of delivery form in optimizing butyrate bioavailability and support the use of lysine-butyrate complexes for enhanced systemic availability.

Study Summary — Butyrate Pharmacokinetic Comparison

Study design:

  • Randomized, three-arm crossover clinical trial in 10 healthy adult men
  • Each participant ingested one form of butyrate per visit
  • Single dose per visit, with blood sampling over ~3.5 hours to measure plasma butyrate kinetics
  • All forms delivered the same 786 mg total butyric acid per dose

Dosing & Time of Use:

  • Lysine butyrate (LysB): 786 mg butyric acid
  • Sodium butyrate (NaB): 786 mg butyric acid
  • Tributyrin (TB): 786 mg butyric acid
  • Monitoring window: 0 – 210 minutes after ingestion

Pharmacokinetic (PK) Results

Serum Butyrate Absorption

Area Under the Curve (AUC₀₋₂₁₀):

  • Lysine butyrate (LysB): ~189 µg·min/mL
  • Sodium butyrate (NaB): ~144 µg·min/mL
  • Tributyrin (TB): ~108 µg·min/mL

→ Both LysB and NaB showed ~75% higher systemic exposure than TB, with LysB tending highest.

Peak concentration (Cmax):

  • LysB: ~4.53 µg/mL
  • NaB: ~2.51 µg/mL
  • TB: ~0.91 µg/mL

→ Lysine butyrate achieved ~500% higher Cmax than TB and ~180% higher Cmax vs sodium butyrate.

Time to peak (Tmax):

  • LysB: ~20 min
  • NaB: ~22.5 min
  • TB: ~51.5 min

→ Both LysB and NaB reached peak levels >2× faster than tributyrin.

Study Conclusions

  • Lysine butyrate (LysB) and sodium butyrate (NaB) both produced significantly higher systemic butyrate exposure than tributyrin (TB) in humans after a single dose.
  • Lysine butyrate tended to produce the highest peak concentration (Cmax) and had comparable AUC to sodium butyrate, while both were superior to tributyrin in terms of speed and extent of absorption.
  • Tributyrin, while a valid butyrate prodrug, showed delayed and lower peak exposure compared with the two direct butyrate salt forms.

Practical Benefits & Real-World Relevance

1. Greater Bioavailability — More Butyrate in Blood Sooner

Lysine butyrate's ~500% higher Cmax vs tributyrin and ~180% higher Cmax vs sodium butyrate means more butyrate enters circulation quickly after ingestion, which can matter when targeting systemic signaling pathways (e.g., immune modulation, metabolic responses).

2. Faster Absorption — Earlier Physiological Impact

Tmax ~20 min for LysB/NaB vs ~51 min for TB indicates that butyrate becomes available to the body 2–3× faster — this could be relevant when butyrate effects are needed acutely (e.g., post-meal signaling).

3. Stronger Systemic Exposure

Higher AUC suggests a larger overall window of exposure over the absorption period — important because blood butyrate levels are linked to systemic anti-inflammatory effects, HDAC modulation, and metabolic signaling pathways.

4. Subjective Well-Being Signals (Exploratory)

Participants also showed time effects in measures like mood, calm/relaxed state, and alertness, suggesting that rapid systemic availability of butyrate may influence neurophysiology or gut–brain signaling — though this is exploratory and should be interpreted cautiously.

Reference Link: https://journalofexerciseandnutrition.com/index.php/JEN/article/view/189



Study 11 Summary

Complete Study Information: https://pubmed.ncbi.nlm.nih.gov/41422374/

Efficacy of microencapsulated sodium butyrate as add-on therapy in inducing remission in patients with mild-to-moderate ulcerative colitis: a multicenter, double-blind, randomized, placebo-controlled study.
Medical Science Monitor. 2024;30:e945684.
doi:10.12659/MSM.945684

Microencapsulated sodium butyrate (MSB) is a colon-targeted formulation of butyric acid designed to deliver butyrate directly to the distal gut where it exerts immune-modulatory and mucosal healing effects. Researchers conducted a large multi-center, double-blind, randomized, placebo-controlled clinical trial to assess MSB as an adjunctive treatment in adults with mild-to-moderate active UC. Participants received MSB at 300 mg twice daily (total 600 mg/day) or placebo, in addition to stable baseline therapies, for 8 weeks. The study demonstrated that MSB significantly increased rates of clinical improvement, clinical remission, endoscopic improvement, and biochemical remission compared with placebo.

Detailed Study Summary

Study design:

  • Multi-center, double-blind, randomized, placebo-controlled clinical trial
  • Patients: Adults with active mild-to-moderate ulcerative colitis
  • Intervention: Microencapsulated sodium butyrate (MSB) 300 mg twice daily (600 mg/day)
  • Control: Placebo (matched capsule)
  • Duration: 8 weeks

Dosing & Time of Use

  • Dosage: 600 mg/day (300 mg twice daily) of microencapsulated sodium butyrate
  • Duration: 8 weeks
  • Administered as adjunct therapy alongside standard UC medications (e.g., mesalazine)

Results – Percent Improvements

Clinical Improvement

  • MSB group: 51% achieved ≥3-point reduction in Total Mayo Score
  • Placebo group: 21.3%
  • Difference: ~30 percentage points higher with MSB (P=0.005)

Clinical Remission

  • MSB group: 31.4% achieved remission (TMS ≤2, no rectal bleeding, normal stool frequency)
  • Placebo group: 6.4%
  • Difference: ~25 percentage points higher with MSB (P=0.004)

Endoscopic Improvement

  • MSB group: 25.5% had ≥1-point reduction in endoscopic score
  • Placebo group: 4.6%
  • Difference: ~20.9 percentage points (P=0.006)

Biochemical Remission

  • MSB group: 41.2% reached fecal calprotectin ≤250 µg/g
  • Placebo group: 17.0%
  • Difference: ~24.2 percentage points (P=0.009)

Note: Endoscopic remission rates (Mayo score = 0) trended higher with MSB but were not statistically significant.

Conclusions from the Findings

  • MSB provided clinically meaningful benefits compared with placebo across symptom reduction, objective disease remission markers, and mucosal improvement in mild-to-moderate UC.
  • Patients on MSB were significantly more likely to achieve clinical and biochemical remission and show evidence of healing on endoscopy.
  • Increases in fecal butyric acid (C4) strongly correlated with improvements in clinical scores, suggesting butyrate availability in the colon may be mechanistically linked to the treatment response.
  • MSB was well tolerated with no safety concerns reported over the 8-week course.

Practical Benefits & Real-World Relevance

✔ Adjunct Efficacy in Standard Care Context
The study demonstrates that adding MSB to conventional UC therapy significantly improves outcomes within 8 weeks — a practical time frame for clinical decision-making.

✔ Meaningful Symptom & Disease Control
Higher clinical improvement and remission rates indicate that patients are more likely to experience reduced symptoms, normalized bowel function, and lower inflammatory burden.

✔ Objective Endoscopic & Biochemical Benefits
Endoscopic improvement and biochemical remission (e.g., fecal calprotectin reduction) are validated surrogate markers of mucosal healing, strongly associated with long-term remission.

✔ Tolerability & Safety
The favorable safety profile supports use in longer courses or chronic management strategies.

Reference Link: https://pubmed.ncbi.nlm.nih.gov/41422374/



Study 12 Summary

Complete Study Information: https://pubmed.ncbi.nlm.nih.gov/24343275/

Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis — a prospective randomized study. Int J Colorectal Dis. 2014;29(3):387-393. doi:10.1007/s00384-013-1807-5

Diverticulosis—characterized by the formation of colonic diverticula—is a common condition, particularly in older adults, and can progress to symptomatic episodes of diverticulitis marked by pain, fever, and inflammation, which often require medical intervention. Researchers investigated whether daily supplementation with microencapsulated sodium butyrate (MSB) could reduce the incidence of diverticulitis in patients with diverticulosis. In a 12-month, randomized, placebo-controlled trial, patients received 300 mg/day of MSB or placebo. The study demonstrated that MSB significantly reduced diverticulitis episodes and improved patient-reported quality of life compared with placebo.

Detailed Summary

Dosing & Duration

  • Supplement: Microencapsulated sodium butyrate (MSB)
  • Dose: 300 mg per day
  • Comparator: Placebo
  • Duration: 12 months
  • Population: 73 randomized; 52 completed study (30 MSB, 22 placebo)

Results & Percentage Improvements

Diverticulitis Episodes

  • MSB group: 2 occurrences total (6.7% incidence)
  • Placebo group: 7 occurrences total (31.8% incidence)
  • Absolute difference: ~25 percentage points fewer diverticulitis episodes with MSB (p = 0.0425)

Ultrasound Confirmed Diverticulitis

  • MSB: 1 event
  • Placebo: 5 events
  • MSB group had fewer diagnostic findings of diverticulitis (p = 0.0229)

Subjective Symptom Improvement / Quality of Life

  • MSB group: 55.7% reported symptom improvement
  • Placebo: 22.7% reported improvement
  • Difference: ~+33 percentage points in perceived relief/QoL with MSB (p = 0.0143)

Safety/Tolerability

  • No adverse effects of MSB reported over the 12-month period

Conclusion of the Findings

In this prospective, randomized clinical trial, daily supplementation with 300 mg microencapsulated sodium butyrate for 12 months significantly reduced the incidence of clinically diagnosed diverticulitis episodes in patients with diverticulosis compared to placebo. Patients receiving butyrate also reported marked improvements in subjective symptoms and overall quality of life, with no safety concerns noted. These results support the concept that colonic delivery of butyrate can enhance mucosal resilience and potentially prevent progression from asymptomatic diverticulosis to symptomatic diverticulitis.

Practical Benefits & Real-World Relevance

1. Real-world prevention of disease progression

A ~25 percentage point reduction in diverticulitis incidence over 12 months is clinically meaningful — especially because diverticulitis can lead to pain, hospitalizations, imaging tests, and even surgery.

2. Improved patient quality of life

Over half of patients taking butyrate reported feeling better, compared with under a quarter with placebo — a large subjective benefit that aligns with real daily symptom relief.

3. Lower health service utilization

Fewer imaging procedures and symptomatic episodes suggest potential to reduce healthcare burden and medical costs.

4. Safe long-term use

Tolerability over a full year with no reported side effects supports safety in a predominantly older outpatient population.

Reference Link: https://pubmed.ncbi.nlm.nih.gov/24343275/



Study 13 Summary

Complete Study Information: https://pubmed.ncbi.nlm.nih.gov/36014789/

Oral Butyrate Supplementation Does Not Improve Disease Activity in Children with Newly Diagnosed Inflammatory Bowel Disease: A Multicenter Randomized Placebo-Controlled Trial.
Nutrients. 2022;14(16):3283.
doi:10.3390/nu14163283

To explore whether butyrate supplementation could benefit pediatric IBD, a multicenter, randomized, double-blind, placebo-controlled trial evaluated the effects of oral sodium butyrate supplementation in children with newly diagnosed Crohn's disease or ulcerative colitis. Participants received butyrate or placebo in addition to standard induction therapy for 12 weeks, with outcomes focused on disease activity, inflammatory biomarkers, microbiome composition, and safety. The study found no significant clinical or biochemical benefit of butyrate supplementation over placebo, highlighting important considerations regarding formulation, delivery, disease stage, and baseline therapy in pediatric populations.

Study Design & Dosing

  • Population: Children with newly diagnosed IBD (Crohn's disease or UC)
  • Design: Multicenter, randomized, double-blind, placebo-controlled trial
  • Intervention: Oral sodium butyrate
  • Dose: 300 mg/day
  • Duration: 12 weeks
  • Background therapy: Standard induction treatment (e.g., corticosteroids, exclusive enteral nutrition)

Results & Percentage Outcomes

Primary Outcome: Disease Activity

  • No statistically significant difference between butyrate and placebo in:
    • Pediatric Crohn's Disease Activity Index (PCDAI)
    • Pediatric Ulcerative Colitis Activity Index (PUCAI)

Percentage improvements were similar in both groups, largely driven by standard induction therapy rather than butyrate supplementation.

Inflammatory Markers

  • Fecal calprotectin: Decreased in both groups; no significant between-group difference
  • CRP and ESR: Improved similarly in butyrate and placebo arms

Microbiome Composition

  • No meaningful increase in fecal butyrate levels
  • No significant enrichment of butyrate-producing taxa
  • Suggests poor colonic delivery or rapid proximal absorption

Safety

  • Butyrate was well tolerated
  • No serious adverse events attributable to supplementation

Conclusions of the Study

In children with newly diagnosed inflammatory bowel disease receiving standard induction therapy, 12 weeks of oral sodium butyrate supplementation at 300 mg/day did not provide additional clinical, biochemical, or microbiome-related benefit compared with placebo. The authors concluded that lack of efficacy may be related to insufficient dosing, suboptimal formulation or colonic delivery, short intervention duration, or masking effects of concurrent induction therapies. Importantly, the study does not negate butyrate's biological relevance but underscores the need for optimized delivery strategies and better-defined target populations.

Practical Benefits & Real-World Relevance (Why This Still Matters)

1. Highlights Importance of Formulation & Delivery

This trial supports the idea that not all oral butyrate formulations behave the same, particularly in pediatric populations — reinforcing why microencapsulation, sustained release, or prodrug forms may be necessary for efficacy.

2. Disease Stage Matters

Children were newly diagnosed and undergoing aggressive induction therapy, which likely overpowered any marginal additive effect from butyrate — a key lesson when interpreting "null" results.

3. Supports Use as Adjunct, Not Induction Therapy

The findings suggest butyrate may be better positioned for maintenance phases, subclinical inflammation, and metabolic or immune modulation rather than acute induction of remission in pediatric IBD.

4. Confirms Safety in Pediatric Use

Despite lack of efficacy, the study reinforces good tolerability, which is valuable for long-term safety profiling.

5. Strengthens Scientific Credibility

Being aware of this study allows confident, evidence-based explanations of why some butyrate studies work and others don't — grounded in formulation, dose, delivery, and disease context.

Reference Link: https://pubmed.ncbi.nlm.nih.gov/36014789/



Study 14 Summary

Complete Study Information: https://pmc.ncbi.nlm.nih.gov/articles/PMC11930386/

Effects of Short Chain Fatty Acid-Butyrate Supplementation on the Disease Severity, Inflammation, and Psychological Factors in Patients With Active Ulcerative Colitis: A Double-Blind Randomized Controlled Trial. J Nutr Metab. 2025 Mar 16;2025:3165876. doi: 10.1155/jnme/3165876. PMID: 40123849; PMCID: PMC11930386

Ulcerative colitis is increasingly recognized as a systemic inflammatory condition with significant psychological and quality-of-life burdens. A randomized controlled trial evaluated the effects of high-dose oral sodium butyrate supplementation (600 mg/kg/day) over 12 weeks in adults with active UC. The study assessed disease severity scores, inflammatory biomarkers and ratios, and validated psychological scales. Results demonstrated that butyrate supplementation significantly improved disease activity, reduced inflammatory burden, and improved psychological well-being compared with placebo, supporting a potential gut–brain modulatory role for butyrate in ulcerative colitis management.

Study Design, Dosing & Duration

  • Design: Randomized, double-blind, placebo-controlled trial
  • Population: Adults with active ulcerative colitis
  • Intervention: Oral sodium butyrate
  • Dose: 600 mg/kg/day
  • Duration: 12 weeks
  • Comparator: Placebo
  • Concurrent therapy: Stable background UC medications allowed

Key Outcomes & Percentage Improvements

Disease Severity

  • Total Mayo Score:
    • Butyrate group: ~41% reduction from baseline
    • Placebo: No significant change
    • Between-group difference statistically significant (p < 0.01)

Inflammation Markers

  • hs-CRP:
    • Butyrate: ↓ ~38%
    • Placebo: No meaningful change
  • Neutrophil-to-Lymphocyte Ratio (NLR):
    • Butyrate: ↓ ~29%
    • Placebo: No significant improvement
  • Platelet-to-Lymphocyte Ratio (PLR):
    • Butyrate: ↓ ~26%
    • Placebo: Unchanged

These ratios are increasingly used as systemic inflammatory burden indicators in IBD.

Psychological Parameters

(All measured via validated questionnaires)

  • Depression scores: ↓ ~34%
  • Anxiety scores: ↓ ~32%
  • Perceived stress: ↓ ~30%

No significant improvements were observed in the placebo group.

Study Conclusions

Twelve weeks of high-dose oral sodium butyrate supplementation significantly improved clinical disease severity, systemic inflammation, and psychological well-being in patients with active ulcerative colitis compared with placebo. The concurrent reduction in inflammatory ratios and improvements in anxiety, depression, and stress scores suggest that butyrate may exert gut–immune–brain modulatory effects, extending benefits beyond mucosal inflammation alone.

Practical Benefits & Real-World Relevance

1. Supports the Gut–Brain Axis Narrative

This is one of the few UC trials demonstrating improvements in mental health parameters alongside inflammatory control, reinforcing butyrate's relevance beyond gut lining support.

2. Systemic Inflammation Reduction

Improved NLR and PLR suggest reduced immune activation that may translate to lower flare risk and improved long-term disease stability.

3. Improved Quality of Life Signals

Reductions in anxiety, depression, and stress have tangible real-world meaning for adherence, daily functioning, and patient satisfaction.

4. Complements Other UC Butyrate Trials

This study pairs well with the microencapsulated sodium butyrate UC RCT (Study 11) and the circadian/sleep UC trial (Study 8), together building a coherent mechanistic and clinical story.

Reference Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC11930386/



Big-Picture Integration with Other Studies

  • Study 1: This study demonstrated that human gut bacteria can metabolize lysine and fructoselysine into butyrate, identifying a novel amino acid–driven pathway for endogenous butyrate production.
  • Study 2: This review outlines how butyrate regulates immune, metabolic, and neurological health through HDAC inhibition, NF-κB suppression, and GPCR signaling pathways.
  • Study 3: This review summarizes how microbiota-derived short-chain fatty acids modulate macrophage function, immune balance, and inflammatory signaling across infectious, inflammatory, and cancer-related conditions.
  • Study 4: This study showed that butyrate strengthens intestinal barrier function by activating AMPK and promoting tight junction assembly in intestinal epithelial cells.
  • Study 5: In a PCOS animal model, sodium butyrate reduced hypothalamic inflammation and improved GABA signaling, highlighting a gut–brain mechanism for neuroimmune regulation.
  • Study 6: In patients with inflammatory bowel disease, microencapsulated sodium butyrate supplementation increased beneficial butyrate-producing gut bacteria and improved quality-of-life outcomes.
  • Study 7: In a 6-month randomized, placebo-controlled trial, weight-adjusted oral butyrate supplementation significantly improved BMI reduction rates and metabolic, inflammatory, and appetite-regulating markers in children and adolescents with obesity compared with standard care alone.
  • Study 8: In a 12-week randomized, placebo-controlled trial, oral sodium butyrate supplementation significantly reduced intestinal and systemic inflammation while improving circadian-clock gene expression, sleep quality, and quality of life in patients with active ulcerative colitis.
  • Study 9: In a 4-week human intervention study, high-dose oral sodium butyrate selectively reduced pro-inflammatory trained immunity responses in circulating monocytes of obese men with metabolic syndrome, without broadly suppressing baseline immune function.
  • Study 10: In a randomized crossover pharmacokinetic trial, lysine butyrate produced faster absorption and higher peak circulating butyrate levels than tributyrin, with comparable or greater systemic exposure than sodium butyrate following a single oral dose.
  • Study 11: In an 8-week double-blind, placebo-controlled RCT in adults with mild-to-moderate ulcerative colitis, microencapsulated sodium butyrate (600 mg/day) significantly increased clinical improvement (51% vs 21%), clinical remission (31% vs 6%), endoscopic improvement (26% vs 5%), and biochemical remission (41% vs 17%) compared with placebo when added to standard therapy.
  • Study 12: In a 12-month randomized, placebo-controlled trial, daily microencapsulated sodium butyrate (300 mg/day) significantly reduced the incidence of diverticulitis episodes and improved patient-reported symptoms and quality of life in individuals with diverticulosis.
  • Study 13: In a 12-week multicenter, randomized, placebo-controlled trial in children with newly diagnosed inflammatory bowel disease, oral sodium butyrate supplementation (300 mg/day) did not provide additional improvement in disease activity or inflammatory markers beyond standard induction therapy.
  • Study 14: In a 12-week randomized, placebo-controlled trial, high-dose oral sodium butyrate (600 mg/kg/day) significantly reduced disease severity and systemic inflammatory ratios while improving anxiety, depression, and stress scores in patients with active ulcerative colitis.

BIOMend® Ingredient Summary & Real-World Relevance

BIOMend® is designed to translate the well-established biology of butyrate into practical, user-friendly supplementation with relevance across digestive, metabolic, immune, and gut–brain health. Clinical and mechanistic studies on oral butyrate demonstrate that restoring butyrate availability can support intestinal mucosal integrity, reduce inflammatory signaling, improve metabolic regulation, and influence immune and neurological pathways. BIOMend® builds on this evidence by offering a form of butyrate that is more tolerable and bioavailable, increasing the likelihood of consistent daily use and meaningful physiological impact.

In real-world settings, this means BIOMend® may help support digestive comfort and colon resilience, particularly in individuals with low fiber intake or disrupted microbiota. Its role in immune modulation and trained immunity suggests relevance for systemic inflammatory balance, especially in metabolically stressed populations. Emerging evidence linking butyrate to circadian rhythm regulation, sleep quality, and psychological well-being highlights additional relevance for the gut–brain axis, an area of growing interest in both clinical and consumer health. Importantly, BIOMend® is positioned as an adjunctive postbiotic strategy, complementing diet, probiotics, and prebiotics rather than replacing them.

BIOMend® offers a practical way to deliver one of the gut microbiome's most important signaling molecules in a form that aligns with real-world needs: stable, tolerable, and biologically relevant across multiple systems influenced by gut health.

Ingredient Manufacturer Link: https://nutrashure.com/ingredients/biomend/

BIOMend® is a clinically studied ingredient used in the following Silver Fern™ Brand product:

Go to full site